Introduction
============

Uterine leiomyomas (ULs) are the most common gynecological benign tumors originating from the myometrium, affecting 60--80% of women of reproductive age ([@b1-ol-0-0-6120]), and resulting in abnormal uterine bleeding, recurrent miscarriage, pelvic pain, premature birth and infertility in 10--30% of cases ([@b2-ol-0-0-6120]--[@b4-ol-0-0-6120]). Clinically, ULs may grow as a single nodule or multiple concurrent lesions. At present, the most effective treatment strategy for ULs is a surgical operation, although certain medical drugs are also available, including gonadotropin-releasing hormone agonists and selective modulators of estrogen- and progesterone-receptors ([@b5-ol-0-0-6120],[@b6-ol-0-0-6120]).

Heterozygous somatic mutations in exon 2 of the mediator complex subunit 12 (MED12) gene located on the X chromosome have been identified in 70.7% (159/225) of tumors with ULs ([@b7-ol-0-0-6120]). Subsequent studies using the same methods or direct Sanger sequencing have also identified prevalent MED12 mutations in ULs ([@b8-ol-0-0-6120]--[@b12-ol-0-0-6120]), breast fibroadenoma ([@b13-ol-0-0-6120],[@b14-ol-0-0-6120]) and chronic lymphocytic leukemia ([@b15-ol-0-0-6120]), whereas MED12 mutations were less common in prostate ([@b16-ol-0-0-6120],[@b17-ol-0-0-6120]) and colorectal cancer ([@b10-ol-0-0-6120],[@b18-ol-0-0-6120]). Almost all identified MED12 mutations in ULs were heterozygous somatic mutations restricted to the 44th codon (p.G44) on exon 2, only occurring at low frequencies in adjacent codons, including codons 33, 36, 41 and 43 ([@b7-ol-0-0-6120]--[@b9-ol-0-0-6120],[@b11-ol-0-0-6120],[@b12-ol-0-0-6120]). MED12 belongs to the mediator complex and modulates RNA polymerase II activity, and thus is involved in global gene transcriptional regulation within cells ([@b7-ol-0-0-6120],[@b19-ol-0-0-6120]). A previous *in vivo* study revealed that the MED12 p.G44D (c.131G\>A) mutation (the most frequently observed mutation in ULs) may cause ULs and uterine hyperplasia in mice ([@b20-ol-0-0-6120]). Additional array comparative genomic hybridization analysis revealed that this mutation markedly increased genomic copy number gains and losses at the whole-genome scale, spanning multiple genes involved in cell cycle checkpoints and tumorigenesis ([@b20-ol-0-0-6120]).

Accumulating evidence has confirmed frequent MED12 mutations in ULs ([@b7-ol-0-0-6120]--[@b12-ol-0-0-6120]). However, several issues regarding MED12 mutations in ULs remain unresolved. First, the clinical impacts of MED12 mutations in ULs remain scarce; only one study has reported that patients with MED12-mutated with ULs tend to harbor smaller sized leiomyomas compared with their counterparts without MED12 mutations ([@b12-ol-0-0-6120]). Second, it is largely unclear whether MED12 mutations also exist in the adjacent myometrium in patients with ULs. Third, the mutational status of MED12 in multiple concurrent leiomyomas within the same affected uterus remains unexplored in Han Chinese patients with ULs. Fourth, increasing evidence has suggested that paralogous genes are frequently mutated in certain cancer types ([@b21-ol-0-0-6120]--[@b23-ol-0-0-6120]), however, it is unknown whether MED12L (the paralogous gene of MED12) is also mutated in ULs.

To clarify these issues, MED12 and MED12L mutations were analyzed in 362 Han Chinese samples with ULs, and the results were compared with their clinical features. A high frequency (158/362, 43.6%) of MED12 mutations were identified in the samples used, and MED12 mutations were demonstrated to be associated with smaller cervical diameters. In addition, MED12 mutations occurred in the adjacent myometrium at a low frequency, and the mutational status of MED12 in concurrent leiomyomas from the same patients exhibited a noticeable difference. By contrast, no MED12L mutations were identified in the present sample set.

Materials and methods
=====================

### Samples and clinical characteristics

A collection of 322 patients with ULs undergoing laparoscopic intracapsular myomectomy, including 362 tumors, 322 adjacent control myometrium and 322 paired peripheral blood lymphocytes, were recruited in the Department of Gynecology, Jiangxi Provincial Maternal and Child Health Hospital (Jiangxi, China) between March 2014 and February 2015. Among these patients, 290 patients had solitary leiomyomas and 32 patients had multiple leiomyomas (72 concurrent leiomyomas). All samples were diagnosed according to gynecological and abdominal ultrasonography examinations, and each patient provided informed consent. The present study conformed to the tenets of the Declaration of Helsinki and was approved by the institutional review board of Jiangxi Provincial Maternal and Child Health Hospital. Clinical characteristics of the patients are summarized in [Tables I](#tI-ol-0-0-6120){ref-type="table"}--[III](#tIII-ol-0-0-6120){ref-type="table"}.

### DNA isolation

Tissue and peripheral blood DNA was isolated with E.Z.N.A. tissue (cat. no. D3396-02) and blood DNA kits (cat. no. D3392-02; Omega Bio-Tek, Inc., Norcross, GA, USA), respectively. The quantity of isolated DNA was assessed using a SmartSpec Plus spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

### MED12 and MED12L mutational analysis

For the mutational analysis of MED12 (NM_005120.2) and the paralogous MED12L (NM_053002.5; [Fig. 1](#f1-ol-0-0-6120){ref-type="fig"}), two pairs of primers were designed to amplify MED12 exons 1 and 2, and MED12L exon 2. The MED12 forward (5′-TTCTCCTGCCCTACTCTCCC-3′) and reverse (5′-GGACCTGGATGGACATTGCA-3′) primers generated a 721 bp polymerase chain reaction (PCR) product; while the MED12L forward (5′-TGAAGCTTTTACATCCTTCTGCT-3′) and reverse (5′-GGGCAGGACGGTATACATGG-3′) primers generated a 296 bp PCR product. For each sample, 50 ng genomic DNA and 2 U LA Taq DNA polymerase (Takara Biotechnology Co., Ltd., Dalian, China) underwent 35 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec and extension at 72°C for 20 sec, in a total volume of 25 µl. These reactions were performed in a Thermal Cycler 2720 (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The PCR products were subsequently sequenced on an ABI Prism 3730 DNA sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.). Sequencing data was analyzed using DNASTAR Lasergene version 7.2 software (DNASTAR, Inc., Madison, WI, USA). The identified mutations were confirmed by bidirectional sequencing, and the somatic mutations of MED12 were verified by sequencing the paired peripheral blood lymphocytes. In addition, the protein sequences of human MED12 (NP_005111.2) and MED12L (NP_443728.3) were obtained from GenBank ([@b24-ol-0-0-6120]) to analyze the sequence homology.

### Statistical analysis

Clinical data was taken at the time of sampling for the screening of molecular alterations. As the majority of patients with multiple leiomyomas harbored wild type and mutant MED12 in different tumors, the samples with multiple leiomyomas were excluded and the available clinical data from 135 patients with single intramural leiomyoma was obtained for statistical analysis. The serum levels of estradiol, progesterone, thyroid stimulating hormone, free triiodothyronine, free thyroxine, α-fetoprotein, carcinoembryonic antigen, squamous cell carcinoma antigen and cancer antigen 125 (CA125) were determined on day 3 of the menstrual cycle using a radioimmunoassay method, using their respective detection kits: estradiol (cat. no. 01010306024), progesterone (cat. no. 01010305024), thyroid stimulating hormone (cat. no. 01010201022), free triiodothyronine (cat. no. 01010202024), free thyroxine (cat. no. 01010203024), α-fetoprotein (cat. no. 01010102022), carcinoembryonic antigen (cat. no. 01010101022), and CA125 (cat. no. 01010104022) from Chemclin (Chemclin, Biotechnology Co., Ltd., Beijing, China), and squamous cell carcinoma antigen (cat. no. 68111LP15) was from Abbott Diagnostics (Santa Clara, CA, USA), as described previously ([@b25-ol-0-0-6120]--[@b27-ol-0-0-6120]). Statistical analyses were performed with SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). Continuous variables were expressed as the mean ± standard deviation and analyzed by independent sample t-tests, and categorical variables were examined with Pearson\'s χ^2^ test for the potential associations between MED12 mutations and the available biological variables. Clinical characteristics of interest were analyzed by logistic regression analysis to confirm statistical significance. All statistical tests were two-sided at the 5% level of significance. P\<0.05 was considered to indicate a statistically significant difference, and all P-values were two-tailed.

Results
=======

### Patient characteristics

Patient characteristics are presented in [Tables I](#tI-ol-0-0-6120){ref-type="table"}--[III](#tIII-ol-0-0-6120){ref-type="table"}.

### Mutation analysis of MED12 and MED12L in ULs

A total of 362 cases with ULs were analyzed for the presence of MED12 and MED12L mutations. MED12 mutations were identified in 158 out of 362 tumors (43.6%). There were 10 types of mutation, including p.L36R (c.107T\>G), p.V41E (c.122T\>A), p.Q43P (c.128A\>C), p.G44S (c.130G\>A), p.G44C (c.130G\>T), p.G44R (c.130G\>C), p.G44D (c.131G\>A), p.G44 V (c.131G\>T), p.G44A (c.131G\>C) and p.F45_A50del (c.133_150del 18; [Fig. 2](#f2-ol-0-0-6120){ref-type="fig"}; [Table IV](#tIV-ol-0-0-6120){ref-type="table"}). Of these mutations, the most prevalent mutation was located on the 44th codon, and MED12 p.G44D (c.131G\>A) was the most common mutation form (42.4%, 67/158). All patients with the mutation were heterozygous and retained a wild type allele, and the somatic status of this sample was confirmed by sequencing the paired peripheral blood ([Fig. 2](#f2-ol-0-0-6120){ref-type="fig"}). In contrast to the frequent MED12 mutations, no MED12L mutations were identified in the 362 samples with ULs ([Fig. 2](#f2-ol-0-0-6120){ref-type="fig"}).

### MED12 mutations in multiple ULs

To determine the frequency of clonally associated ULs in the samples, 72 concurrent tumors from 32 patients with multiple leiomyomas were analyzed for the presence of MED12 mutations. A total of 45 tumors from 20 patients exhibited discordant mutation status of MED12, indicating that these tumors were clonally independent ([Table V](#tV-ol-0-0-6120){ref-type="table"}).

### MED12 mutations in adjacent control myometrium

A total of 145 adjacent control myometrium adjacent to MED12-mutated tumors were analyzed for the presence of MED12 mutations by direct DNA sequencing. Two myometrium (2/145, 1.4%) were revealed to harbor MED12 mutations. Control myometrium from samples 387 and 395 harbored MED12 p.G44D (c.131G\>A) and p.G44S (c.130G\>A) mutations, respectively ([Table VI](#tVI-ol-0-0-6120){ref-type="table"}), while the remaining 143 myometrium did not harbor MED12 mutations.

### Association between MED12 mutations, clinical features and biological characteristics

Of the 322 patients, MED12-mutated tumors tended to have smaller cervical diameters \[odds ratio (OR)=0.181; 95% confidence interval, 0.036--0.919; P\<0.05; [Tables I](#tI-ol-0-0-6120){ref-type="table"} and [VII](#tVII-ol-0-0-6120){ref-type="table"}\]. However, MED12 mutations were not associated with any other clinical characteristics, including age of menarche and the first delivery, number of pregnancies, deliveries and abortions, menstrual cycle and menstruation, or serum levels of estradiol, progesterone and CA125 ([Tables I](#tI-ol-0-0-6120){ref-type="table"}--[III](#tIII-ol-0-0-6120){ref-type="table"}).

Discussion
==========

Prevalent MED12 mutations have been detected in ULs ([@b8-ol-0-0-6120]--[@b12-ol-0-0-6120]), breast fibroadenoma ([@b13-ol-0-0-6120],[@b14-ol-0-0-6120]) and chronic lymphocytic leukemia ([@b15-ol-0-0-6120]). Evolutionary conservation analysis results have demonstrated that these mutations were evolutionarily conserved from yeast to humans ([@b18-ol-0-0-6120]). Furthermore, transgenic mice expressing MED12 p.G44D mutations demonstrated increased genomic instability, uterine hyperplasia and ULs ([@b20-ol-0-0-6120]).

Previous studies have revealed variable frequencies of MED12 mutations in ULs, ranging from 0--84.1% ([@b7-ol-0-0-6120],[@b8-ol-0-0-6120],[@b10-ol-0-0-6120]--[@b12-ol-0-0-6120],[@b28-ol-0-0-6120]--[@b37-ol-0-0-6120]). Among which, MED12 mutation frequencies in Han Chinese UL samples were 29.3% (49/167) ([@b35-ol-0-0-6120]), 52.5% (95/181) ([@b33-ol-0-0-6120]) and 54.4% (93/171) ([@b38-ol-0-0-6120]), respectively, within the previously observed frequency. In the present study, the mutation frequency of MED12 in the UL samples was 158/362 (43.6%), within the range of these previous observations ([@b7-ol-0-0-6120],[@b8-ol-0-0-6120],[@b10-ol-0-0-6120]--[@b12-ol-0-0-6120],[@b28-ol-0-0-6120]--[@b37-ol-0-0-6120]). In addition, the prevalent MED12 mutations in Han Chinese ULs observed in the present study as well as previous studies ([@b35-ol-0-0-6120],[@b38-ol-0-0-6120]) indicated that MED12 mutations may be actively involved in the pathogenesis of ULs in Han Chinese patients. It was hypothesized that the variation of MED12 mutations in ULs may be caused by disease heterogeneity, as ULs are subdivided into multiple different subtypes ([@b28-ol-0-0-6120],[@b35-ol-0-0-6120],[@b37-ol-0-0-6120]).

MED12 mutations have been investigated broadly in samples with ULs ([@b7-ol-0-0-6120],[@b8-ol-0-0-6120],[@b10-ol-0-0-6120]--[@b12-ol-0-0-6120],[@b28-ol-0-0-6120]--[@b37-ol-0-0-6120]). However, only one study has explored the potential associations between MED12 and several clinical features, which analyzed a total of 164 ULs from Finnish patients and identified that MED12 mutations were associated with smaller tumor size and a larger number of tumors in multiple leiomyomas ([@b12-ol-0-0-6120]). Similarly, the present results also revealed that patients with MED12-mutated tumors tended to have smaller cervical diameters when compared with patients with MED12 wild type tumors. The consistent observations in this previous and present study indicated that MED12 mutations were inversely associated with cervix size in ULs. In addition, in the present study, no associations were observed between MED12 mutations and other available clinical data, including age of menarche and the first delivery, numbers of pregnancies, deliveries and abortions, menstrual cycle and menstruation, or serum levels of estradiol, progesterone and CA125 ([@b12-ol-0-0-6120]).

Previous studies have also attempted to determine whether MED12 mutations also existed in the adjacent control myometrium of ULs ([@b7-ol-0-0-6120],[@b31-ol-0-0-6120],[@b34-ol-0-0-6120],[@b39-ol-0-0-6120],[@b40-ol-0-0-6120]). MED12 mutations were identified in 2 out of 13 (15%) cases in myometrium adjacent to leiomyomas ([@b39-ol-0-0-6120]), while several other studies did not detect MED12 mutations in the control myometrium ([@b7-ol-0-0-6120],[@b31-ol-0-0-6120],[@b34-ol-0-0-6120],[@b40-ol-0-0-6120]). A low frequency of MED12 mutations was detected in 2 out of 145 (1.4%) adjacent control myometrium with MED12 mutations in the tumors ([Table IV](#tIV-ol-0-0-6120){ref-type="table"}). The exact reason for the differential MED12 mutation frequency in control myometrium was unclear, however, the presence of MED12 mutations in the adjacent myometrium in ULs indicated that MED12 mutation may be an early event in the development of ULs in certain cases.

The MED12 mutation status in concurrent tumors from multiple leiomyomas supported several previous observations that the majority of these tumors arise independently ([@b7-ol-0-0-6120],[@b9-ol-0-0-6120]).

In contrast to the high frequency of MED12 mutations in ULs, no mutations were detected in the paralogous MED12L in the present sample cohort, indicating that MED12L mutations may not be common in ULs.

In summary, the present study observed prevalent MED12 mutations in UL samples. Positive MED12 mutations were associated with the diameter of uterine cervix in ULs. Furthermore, MED12 mutations were observed at low frequencies in adjacent control myometrium in ULs, indicating that MED12 mutation may be an early event in the pathogenesis of a proportion of ULs. Furthermore, MED12 mutation status in concurrent tumors from multiple leiomyomas supported several prior observations that the majority of these tumors arise independently.
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###### 

Association of mediator complex subunit 12 mutations with clinical characteristics in 135 uterine leiomyomas.

  Features                            Sample, n   Wild type, n   Wild type       Mutant type, n   Mutant type     P-value
  ----------------------------------- ----------- -------------- --------------- ---------------- --------------- ---------
  Total                               135         86                             49                               
  Age (years)                         135         86             41.51±6.52      49               39.61±7.09      0.12
  Duration of disease (months)        135         86             30.05±41.65     49               32.19±39.46     0.78
  Age of menarche (years)             129         82             14.61±1.64      47               14.11±1.46      0.088
  Age of the first delivery (years)   117         76             23.07±2.62      41               22.88±2.63      0.718
  Number of pregnancies (times)       135         86               3.05±1.49     49                 3.06±1.64     0.96
  Number of deliveries (times)        135         86               1.67±0.89     49                 1.63±0.95     0.85
  Number of abortions (times)         135         86               1.37±1.49     49                 1.39±1.27     0.95
  Cervical diameter (cm)              132         84               3.15±0.32     48                 3.04±0.22     0.030
  Haemoglobin (g/l)                   135         86             109.09±21.60    49               111.53±21.10    0.53
  Estrogen level (pg/ml)                74        44             157.02±137.44   30               135.89±111.65   0.49
  Progesterone (ng/ml)                66          39               1.48±3.31     27                 0.76±0.86     0.27
  TSH (mIU/ml)                        128         83               2.99±2.04     45                 3.19±4.43     0.73
  FT3 (pg/ml)                         128         83               2.89±0.35     45                 2.86±0.38     0.70
  FT4 (ng/dl)                         128         83               1.20±0.19     45                 1.20±0.13     0.84
  AFP (ng/ml)                         130         83               2.28±1.43     47                 2.00±0.79     0.23
  CEA (ng/ml)                         130         83               1.21±0.631    47                 1.18±0.64     0.79
  CA125 (µ/ml)                        131         84             17.97±11.06     47               27.21±58.83     0.16
  SCC (ng/ml)                         129         82               1.74±1.52     47                 1.65±1.25     0.73
  HPV infection (pg/ml)                 92        61               3.61±21.38    31                 4.14±13.73    0.90
  White blood cell count (×10^9^)     135         86               5.95±2.02     49                 5.64±1.65     0.37
  Lymphocyte cell count (×10^9^)      135         86               1.73±0.51     49                 1.70±0.41     0.75
  Mononuclear cell count (×10^9^)     135         86               0.48±0.18     49                 0.43±0.14     0.15
  Neutrophil count (×10^9^)           135         86               0.10±0.07     49                 0.17±0.21     0.0023

AFP, α-fetoprotein; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; FT4, free thyroxine; CEA, carcinoembryonic antigen; CA125, cancer antigen 125; SCC, squamous cell carcinoma; HPV, human papillomavirus.

###### 

Association between mediator complex subunit 12 mutations and clinical characteristics in 135 uterine leiomyomas.

                     Wild type (n=86)   Mutant type (n=49)               
  ------------------ ------------------ -------------------- ----- ----- ------
  Menstruation       79                   7                  48      1   0.26
  Menstrual cycle    78                   8                  45      4   1.00
  Caesarean birth                                                        0.32
    Yes                9                                       8         
    No                                  77                         41    
  Cervical erosion   48                 38                   31    18    0.93

###### 

Association between mediator complex subunit 12 mutations and clinical characteristics in 135 uterine leiomyomas.

                    Wild type, n   Mutant type, n                        
  ----------------- -------------- ---------------- ----- ---- ---- ---- ------
  Menstrual blood                                                        0.51
    None              5                                   1              
    Less                           65                          40        
    Common                                          15              1    
  Dysmenorrhea      72               6                8   35   12   16   0.24

###### 

Mutation frequencies and forms of mediator complex subunit 12 in tumors with uterine leiomyomas.

  Disease          Nucleotide change   Protein change   No. mutated samples, frequency (%)
  ---------------- ------------------- ---------------- ------------------------------------
  Solitary                                              
                   c.107G\>T           p.L36R           5/290 (1.7)
                   c.122T\>A           p.V41E           1/290 (0.3)
                   c.128A\>C           p.Q43P           1/290 (0.3)
                   c.130G\>A           p.G44S           14/290 (4.8)
                   c.130G\>T           p.G44C           9/290 (3.1)
                   c.130G\>C           p.G44R           5/290 (1.7)
                   c.131G\>A           p.G44D           53/290 (18.3)
                   c.131G\>T           p.G44V           22/290 (7.6)
                   c.131G\>C           p.G44A           8/290 (2.8)
                   c.133_150del 18     p.F45_A50del     3/290 (0.7)
  Total multiple                                        121/290 (42.4)
                   c.107G\>T           p.L36R           4/72 (5.6)
                   c.130G\>A           p.G44V           2/72 (2.8)
                   c.130G\>T           p.G44C           4/72 (5.6)
                   c.130G\>C           p.G44R           4/72 (5.6)
                   c.131G\>A           p.G44D           14/72 (19.4)
                   c.131G\>T           p.G44S           2/72 (2.8)
                   c.131G\>C           p.G44A           7/72 (9.7)
  Total combined                                        37/72 (51.4)
                   c.107G\>T           p.L36R           9/362 (2.5)
                   c.122T\>A           p.V41E           1/362 (0.3)
                   c.128A\>C           p.Q43P           1/362 (0.3)
                   c.130G\>A           p.G44S           16/362 (4.4)
                   c.130G\>T           p.G44C           13/362 (3.6)
                   c.130G\>C           p.G44R           9/362 (2.5)
                   c.131G\>A           p.G44D           67/362 (18.5)
                   c.131G\>T           p.G44V           24/362 (6.6)
                   c.131G\>C           p.G44A           15/362 (4.1)
                   c.133_150del 18     p.F45_A50del     3/362 (0.8)
  Total                                                 158/362 (43.6)

###### 

MED12 mutation analysis in concurrent tumors from patients with multiple leiomyomas.

  Sample no.   Tumor no.   MED12 status
  ------------ ----------- -------------------
  198          198T1       WT
  198          198T2       c.107T\>G, p.L36R
  200          200T1       c.131G\>A, p.G44D
  200          200T2       WT
  224          224T1       c.131G\>T, p.G44V
  224          224T2       c.130G\>C, p.G44R
  366          366T1       c.130G\>C, p.G44R
  366          366T2       c.131G\>A, p.G44D
  388          388T1       c.131G\>A, p.G44D
  388          388T2       c.107T\>G, p.L36R
  391          391T1       WT
  391          391T2       WT
  391          391T3       WT
  411          411T1       WT
  411          411T2       WT
  411          411T3       WT
  415          415T1       c.130G\>T, p.G44C
  415          415T2       c.130G\>C, p.G44R
  415          415T3       WT
  416          416T1       c.131G\>A, p.G44D
  416          416T2       c.131G\>T, p.G44V
  420          420T1       c.131G\>A, p.G44D
  420          420T2       c.131G\>A, p.G44D
  420          420T3       c.131G\>A, p.G44D
  422          422T1       c.130G\>T, p.G44C
  422          422T2       c.131G\>C, p.G44A
  423          423T1       c.130G\>T, p.G44C
  423          423T2       WT
  424          424T1       c.130G\>T, p.G44C
  424          424T2       c.131G\>C, p.G44A
  459          459T1       WT
  459          459T2       c.131G\>C, p.G44A
  481          481T1       c.107T\>G, p.L36R
  481          481T2       WT
  481          481T3       WT
  482          482T1       WT
  482          482T2       WT
  488          488T1       c.130G\>A, p.G44S
  488          488T2       WT
  489          489T1       WT
  489          489T2       WT
  491          491T1       c.131G\>A, p.G44D
  491          491T2       c.131G\>C, p.G44A
  494          494T1       c.131G\>C, p.G44A
  494          494T2       c.130G\>A, p.G44S
  497          497T1       WT
  497          497T2       WT
  498          498T1       WT
  498          498T2       WT
  499          499T1       c.131G\>A, p.G44D
  499          499T2       WT
  500          500T1       c.131G\>A, p.G44D
  500          500T2       c.131G\>A, p.G44D
  501          501T1       WT
  501          501T2       WT
  504          504T1       WT
  504          504T2       WT
  506          506T1       WT
  506          506T2       c.107T\>G, p.L36R
  524          524T1       WT
  524          524T2       WT
  530          530T1       c.131G\>A, p.G44D
  530          530T2       c.131G\>A, p.G44D
  530          530T3       c.131G\>C, p.G44A
  531          531T1       c.131G\>C, p.G44A
  531          531T2       c.131G\>A, p.G44D
  531          531T3       WT
  576          576T1       WT
  576          576T2       WT
  580          580T1       c.130G\>C, p.G44R
  580          580T2       WT
  580          580T3       WT

WT, wild type; MED12, mediator complex subunit 12.

###### 

MED12 mutation analysis in adjacent control myometrium in patients with uterine leiomyomas.

  Patient number   Tissue                MED12 mutation
  ---------------- --------------------- -------------------
  387              Leiomyoma             c.130G\>A, p.G44S
                   Adjacent myometrium   c.131G\>A, p.G44D
  395              Leiomyoma             c.130G\>C, p.G44R
                   Adjacent myometrium   c.130G\>A, p.G44S

MED12, mediator complex subunit 12.

###### 

Logistic regression analysis demonstrating that mediator complex subunit 12 mutations are associated with smaller cervical diameters in uterine leiomyomas.

  Feature             Odds ratio (95% confidence interval)   P-value
  ------------------- -------------------------------------- ---------
  Cervical diameter   0.181 (0.036--0.919)                   0.039
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